Novogen Limited (KZIA)
(Delayed Data from NSDQ)
$0.37 USD
-0.02 (-4.88%)
Updated Apr 25, 2024 03:57 PM ET
After-Market: $0.36 -0.01 (-2.70%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
KZIA 0.37 -0.02(-4.88%)
Will KZIA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for KZIA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for KZIA
Beat the Market the Zacks Way: Kazia Therapeutics, Uber, Medtronic in Focus
Novogen Limited (KZIA) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
KZIA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Novogen Limited (KZIA) Could Find Support Soon, Here's Why You Should Buy the Stock Now
Here's Why Novogen Limited (KZIA) Is a Great 'Buy the Bottom' Stock Now
Other News for KZIA
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Why NextPlat Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket
Why Byrna Technologies Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases
Kazia Therapeutics licenses paxalisib to Sovargen